Professor of Pathology and Cell Biology at Columbia University Irving Medical Center

Director of the Columbia University Laboratory of Personalized Genomic Medicine. 

Program Director, Molecular Genetic Pathology Fellowship Program, New York Presbyterian Hospital - Columbia Campus

Board Certification:

Pathology (AP/CP):    American Board of Pathology, March 1998

Molecular Genetic Pathology: American Board of Pathology and American College of Medical Genetics, September 2003.

B.  Positions, Scientific Appointments, and Honors

Positions and Employment:

July 1998-June 1999: Instructor in Clinical Pathology, Columbia University, College of Physicians and Surgeons, 630 W. 168^th, Street, New York NY 10032. Associate Director of Molecular Pathology. Assistant Attending in Pathology, New York Presbyterian Hospital, Columbia Presbyterian Campus, New York NY 10032

July 1999 to November 2007:  Assistant Professor of Clinical Pathology, Columbia University, College of Physicians and Surgeons, 630 W. 168^th Street, New York NY 10032. Associate Director, Molecular Pathology Laboratory;  Director, Immunopathology Laboratory (July1999-June2003); Assistant Attending in Pathology, New York Presbyterian Hospital, New York NY 10032.

November 2007 to Present: Director, Molecular Pathology Laboratory, renamed Personalized Genomic Medicine Laboratory, Columbia University Medical Center; Assistant Attending in Pathology, New York Presbyterian Hospital, New York, NY

July 2008 to June 2021: Associate Professor of Pathology and Cell Biology  at CUIMC, Columbia University College of Physicians and Surgeons.

July 2021to Present: Professor of Pathology and Cell Biology at CUIMC, Columbia University Vagelos College of Physicians and Surgeons.

C.        Contributions to Science

My work with Pediatric Oncology at Columbia University Medical Center helped establish the PIPSEQ (Precision in Pediatric Sequencing) program at the Medical Center. This established clinical whole exome and whole transcriptome sequencing for pediatric cancer patients at the medical center and then for the entire greater New York area. This demonstrated clinical utility of whole exome and whole transcriptome sequencing in advanced pediatric cancer, including the utility of germline variant detection, secondary findings in addition to targetable variants and fusions; identified novel fusions; and demonstrated the role of integrative analysis in advanced cancer.

1. Tannenbaum-Dvir S, Glade Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000471. doi: 10.1101/mcs.a000471
2. Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.Genome Med. 2016;8:133
3. Hsiao SJ, Karajannis MA, Diolaiti D, Mansukhani MM, Bender JG, Kung AL, Garvin JH Jr. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma. Cold Spring Harb Mol Case Stud. 2017;3:a001396.
4. Marks LJ, Oberg JA, Pendrick D, Sireci AN, Glasser C, Coval C, Zylber RJ, Chung WK, Pang J, Turk AT, Hsiao SJ, Mansukhani MM, Glade Bender JL, Kung AL, Sulis ML. Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. Front Pediatr. 2017;5:265. doi: 10.3389/fped.2017.00265. eCollection 2017

The CCCP assay developed in the laboratory has been used to evaluate recurrent mutational events in anorectal melanomas, breast-implant associated anaplastic large cell lymphomas, dural marginal zone lymphomas, T- and NK-cell and post-transplant lymphoproliferative disorders.

1. Ganapathi KA, Jobanputra V, Iwamoto F, Jain P, Chen J, Cascione L, Nahum O, Levy B, Xie Y, Khattar P, Hoehn D, Bertoni F, Murty VV, Pittaluga S, Jaffe ES, Alobeid B, Mansukhani MM, Bhagat G. The genetic landscape of dural marginal zone lymphomas. Oncotarget. 2016;7:43052-43061
2. Margolskee E, Jobanputra V, Jain P, Chen J, Ganapathi K, Nahum O, Levy B, Morscio J, Murty V, Tousseyn T, Alobeid B, Mansukhani M, Bhagat G. Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget. 2016;7:37636-37648.
3. Yang HM, Hsiao SJ, Schaeffer DF, Lai C, Remotti HE, Horst D, Mansukhani MM, Horst BA. Identification of recurrent mutational events in anorectal melanoma. Mod Pathol. 2017;30:286-296
4. Di Napoli A, Jain P, Duranti E, Margolskee E, Arancio W, Facchetti F, Alobeid B, Santanelli di Pompeo F, Mansukhani M, Bhagat G. Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A. Br J Haematol. 2018;180(5):741-744. doi: 10.1111/bjh.14431. Epub 2016 Nov 10

My work with thoracic oncology helped establish the first clinically validated miRNA assay to distinguish pulmonary adenocarcinomas from squamous cell carcinomas, demonstrated the role of targetable MET mutations in pulmonary sarcomatiod carcinomas, and the role of molecular testing in distinguishing multiple primaries from intrapulmonary metastases, in the staging of lung cancer, and the cytomorphological features of ALK-rearranged pulmonary adenocarcinomas.

1. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M. A diagnostic assay based on hsa-miR-205 expression distinguishes squamous from non-squamous non small-cell lung carcinoma. J. Clin Oncol. 2009;27:2030-7. Epub 2009 Mar 9.
2. Pareja F, Crapanzano JP, Mansukhani MM, Bulman WA, Saqi A. Cytomorphological features of ALK-positive lung adenocarcinomas: Psammoma bodies and signet ring cells. Cancer Cytopathol.. 2015;123:162-70 Epub 2014 Dec 29
3. Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, Mansukhani M, Koul S, Halmos B, Borczuk AC. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. J Clin Oncol. 2016;34:794-802. Epub 2015 Jul 27
4. Asmar R, Sonett JR, Singh G, Mansukhani MM, Borczuk AC. Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience. J Thorac Oncol. 2017;12:1524-1535. Epub 2017 Jun 21

My collaborations with the Murty lab, helped dissect the molecular pathogenesis of germ cell neoplasms cervical cancer, and renal neoplasms.

1. Koul S, Houldsworth J, Mansukhani MM, Donadio A, McKiernan JM, Reuter VE, Bosl GJ, Chaganti RS, Murty VV. Characteristic Promoter Hypermethylation Signatures in Male Germ Cell Tumors.  2002; Mol Cancer 1: 8
2. Narayan G,  Arias-Pulido H,  Nandula SV,  Basso K,  Sugirtharaj DD, Vargas H,   Mansukhani M,  Villella J,  Meyer L,  Schneide A,  Gissmann L, Durst M,  Pothuri M,   Murty VVVS. Promoter Hypermethylation of FANCF: Disruption of Fanconi Anemia-BRCA Pathway in Cervical Cancer . Cancer Res  2004; 64: 2994–2997.
3. Narayan G, Xie D, Ishdorj G, Scotto L, Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A, Arias-Pulido H, Murty VV. Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer. Genes Chromosomes Cancer. 2016;55:177-89. Epub 2015 Nov 6
4. Anderson CB, Lipsky M, Nandula SV, Freeman CE, Matthews T, Walsh CE, Li G, Szabolcs M, Mansukhani MM, McKiernan JM, Murty VV. Cytogenetic analysis of 130 renal oncocytomas identify three distinct and mutually exclusive diagnostic classes of chromosome aberrations. Genes Chromosomes Cancer. 2019 May 21. doi: 10.1002/gcc.22766. [Epub ahead of print]

Complete List of Published Work in MyBibliography:

https://www.ncbi.nlm.nih.gov/myncbi/1nOQrV26D9KkT/bibliography/public/